Litigation Details for Purdue Pharma L.P. v. Intellipharmaceutics International Inc. (D. Del. 2017)
✉ Email this page to a colleague
Purdue Pharma L.P. v. Intellipharmaceutics International Inc. (D. Del. 2017)
| Docket | ⤷ Try a Trial | Date Filed | 2017-04-07 |
| Court | District Court, D. Delaware | Date Terminated | 2020-07-28 |
| Cause | 35:271 Patent Infringement | Assigned To | Richard Gibson Andrews |
| Jury Demand | None | Referred To | |
| Patents | 8,309,060; 9,060,976; 9,073,933; 9,492,389; 9,492,391; 9,522,919 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Purdue Pharma L.P. v. Intellipharmaceutics International Inc.
The small molecule drugs covered by the patents cited in this case are ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , and ⤷ Try a Trial .
Details for Purdue Pharma L.P. v. Intellipharmaceutics International Inc. (D. Del. 2017)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2018-05-31 | 123 | Notice of Service | . Wuts, Ph.D. on the Invalidity of U.S. Patents Nos. 9,073,933 B2 and 9,522,919 B2 filed by Intellipharmaceutics…2017 28 July 2020 1:17-cv-00392 830 Patent None District Court, D. Delaware | External link to document |
| 2018-06-11 | 126 | Notice of Service | , Ph.D. on the Non-Infringement of U.S. Patent Nos. 9,073,933 B2 and 9,522,919 B2 filed by Intellipharmaceutics…Non-Infringement of the Asserted Claims of the '993 and '919 Patents and Supplemental Expert Report of Neil E. Spingarn…Invalidity of the Asserted Claims of the '993 and '919 Patents; and (4) Rebuttal Expert Report of Peter G.M. Wuts…2017 28 July 2020 1:17-cv-00392 830 Patent None District Court, D. Delaware | External link to document |
| 2018-07-06 | 130 | Opinion - Memorandum Opinion | of multiple terms in U.S. Patent Nos. 9,060,976 ("the '976 patent"), 9,073 ,933 ("…construction for multiple terms in U.S. Patent Nos. 9,060,976, 9,073,933, 9,522,919, 9,492,389, and 9,…quot;the ' 933 patent"), 9,522,919 ("the ' 919 patent"), 9,492,389 ("the &… ' 389 patent"), and 9,492,391 ("the '391 patent"). The Court has considered…would infringe six of Plaintiffs' patents. (D.I. 1). The patents-in-suit relate to OxyContin®, an extended-release | External link to document |
| 2018-08-03 | 144 | Notice of Service | , Ph.D. on the Non-Infringement of U.S. Patent Nos. 9,060,976; 9,492,389; 9,492,391 filed by Intellipharmaceutics…2017 28 July 2020 1:17-cv-00392 830 Patent None District Court, D. Delaware | External link to document |
| 2019-07-19 | 204 | Notice of Service | Ph.D., on the Non-Infringement of U.S. Pat. Nos. 9,060,976; 9,492,389 filed by Intellipharmaceutics Corporation…2017 28 July 2020 1:17-cv-00392 830 Patent None District Court, D. Delaware | External link to document |
| 2019-07-22 | 205 | Notice of Service | , Ph.D. on the Non-Infringement of U.S. Patent Nos. 9,073,933 B2 and 9,522,919 B2 filed by Intellipharmaceutics…2017 28 July 2020 1:17-cv-00392 830 Patent None District Court, D. Delaware | External link to document |
| 2020-07-29 | 240 | Patent/Trademark Report to Commissioner of Patents | ,073,933; 9,522,919; 9,492,389; 9,492,391; 8,309,060. (Attachments: # 1 Order)(nms) (Entered: 07/29/2020… Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,060,976; 9,073,933…2017 28 July 2020 1:17-cv-00392 830 Patent None District Court, D. Delaware | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
